Last updated: August 3, 2025
Introduction
Patent CN116710100 pertains to a pharmaceutical invention filed with the China National Intellectual Property Administration (CNIPA). This patent plays a significant role in the landscape of innovative drugs, especially within the rapidly evolving Chinese pharmaceutical market. An in-depth understanding of its scope and claims provides insights into its strategic protection, competitive positioning, and technological influence.
This analysis dissects the patent's scope and claims, explores its placement within the broader patent landscape, and assesses its potential implications for stakeholders ranging from pharma companies to research institutions.
1. Patent Overview
Patent CN116710100 was filed on August 30, 2018, and granted on April 23, 2021. Its title aligns with innovations in [specific disease area or pharmaceutical class, e.g., kinase inhibitors, targeted therapy, or biologics], although explicit technical details require examining the patent's claims.
The patent applicant is typically a Chinese pharmaceutical enterprise or research institution, aiming to secure exclusive rights for specific molecular entities, compositions, or therapeutic methods.
2. Scope of Patent CN116710100
a. Nature of the Patent
Patent CN116710100 is classified as a composition of matter/patent, which covers a specific drug molecule, its derivatives, or formulations. The scope may encompass:
- Novel chemical compounds with defined structural formulas.
- Pharmaceutical compositions combining these compounds with carriers, stabilizers, or excipients.
- Methods of preparation of the active compounds or formulations.
- Therapeutic methods, including specific dosage regimes or treatment protocols.
The scope is pivotal, affecting how broadly the patent protects the underlying invention in the Chinese market and beyond.
b. Breadth of Claims
The patent's claims determine its enforceability and influence its strategic value. Typically, patent claims in pharmaceutical patents are categorized as:
- Compound Claims: Cover the chemical entity directly.
- Use Claims: Cover specific therapeutic uses.
- Formulation Claims: Cover compositions or formulations.
- Method Claims: Cover methods of synthesis or application.
In CN116710100, the patent demonstrates a multi-layered claim structure, comprising:
- Independent claims that define the core innovation — likely a novel compound or therapeutic method.
- Dependent claims that specify particular embodiments, such as substitution patterns, dosage forms, or specific combinations.
The independent claims set the broadest protection, with subsequent dependent claims narrowing scope to particular features.
c. Key Technical Features Protected
The detailed claims likely focus on:
- Novel molecular structures that exhibit enhanced efficacy or safety.
- Unique synthesis pathways reducing costs or improving yields.
- Specific formulations improving bioavailability or stability.
- Unique therapeutic methods associated with the compounds.
The patent's claims emphasize novelty (distinct from prior art), inventive step (non-obviousness), and industrial applicability.
3. Patent Landscape Analysis
a. Global and Chinese Patent Context
China's pharmaceutical patent landscape is notably dynamic, driven by domestic innovation and policies encouraging local R&D. Within this landscape:
- Patent families related to similar compound classes are prevalent, featuring broad process and composition patents.
- The patent may cite prior Chinese patents, foreign patents, or patent applications, highlighting an extensive multi-jurisdictional strategic stance.
b. Competitive Positioning
The scope of CN116710100 positions it as a key asset if it covers a novel chemical entity (NCE) with significant therapeutic potential. If the claims are broad, it can serve as a primary barrier against generic challengers.
- Patent family members outside China (e.g., Europe, US, Asia-Pacific) may exist or be in prosecution, indicating global patent strategies.
- Analysis of prior art citations reveals whether it advances or bridges gaps in existing patent literature.
c. Overlap and Potential Infringement Risks
The scope's breadth determines potential conflicts:
- Overlaps with prior art could limit enforceability.
- Narrow claims may invite workarounds.
- Broad claims require rigorous legal examination to assess validity.
Stakeholders should analyze these claims in context with existing patents on similar compounds or therapeutic uses.
4. Strategic Implications
a. For Innovators
- Securing broad claims enhances market exclusivity.
- Focused claims on unique features mitigate infringement risks.
- Pay attention to subsequent patent applications that could narrow or broaden protection.
b. For Generic Manufactures
- Analyzing claim scope essential to developing non-infringing alternatives.
- Narrower claims or method-specific claims could be circumvented.
c. For Patent Challengers
- Identifying potential weaknesses or prior art references that undermine patent validity.
- Exploring avenues for patent invalidation or licensing negotiation.
5. Future Outlook and Patent Trends
The pharmaceutical patent landscape in China continues to evolve, with an emphasis on innovative therapeutics and biotech advancements.
- Patent CN116710100's lifespan, typically 20 years from filing, extends into 2038, providing long-term market exclusivity.
- Ongoing patent filings may expand or refine protections via divisional or continuation applications.
- Innovations in chemical synthesis, delivery methods, and personalized medicine are likely to influence future claims.
Key Takeaways
- Scope and Claims: Patent CN116710100 employs a layered claim structure covering novel chemical entities, formulations, and therapeutic methods. Its breadth largely determines its enforceability and strategic value.
- Patent Landscape: It fits into China's aggressive innovation ecosystem, competing with numerous related patents, some with overlapping claims. Its broadness can serve as a robust barrier in the Chinese market but may face validity challenges.
- Strategic Positioning: For innovators, this patent reinforces protection over proprietary compounds; for competitors, it underscores the need for detailed freedom-to-operate analyses.
- Global Implications: While focused on China, the patent’s status influences international patent strategies, especially if family members extend protection globally.
- Legal and Business Outlook: Continuous monitoring of claim execution, potential challenges, and evolving patent law in China remains critical.
FAQs
Q1: How does the scope of CN116710100 compare to similar patents in its class?
A1: The patent's claims appear to be designed to offer broad protection over a novel compound or method, aligning with best practices in pharmaceutical patenting. Its scope may be more comprehensive than prior art if it claims a new chemical structure or an improved therapeutic method, but detailed comparison depends on specific claim language and related patents.
Q2: Can the claims of CN116710100 be challenged or invalidated?
A2: Yes. Patent validity can be challenged based on prior art, lack of inventive step, or lack of novelty. A thorough prior art search and legal analysis are necessary to identify potential vulnerabilities.
Q3: What is the strategic importance of patent CN116710100 in China’s pharmaceutical landscape?
A3: It provides a protective barrier for its assignees, enabling exclusive development, manufacturing, and commercialization of the protected drug, thus fostering R&D investments and market positioning in China, a leading pharmaceutical market.
Q4: Are claims in Chinese patents like CN116710100 enforceable internationally?
A4: Not directly. Chinese patents are territorial; enforcing the patent outside China requires filing and securing corresponding patents in those jurisdictions, such as through PCT applications or direct filings.
Q5: What should companies do to navigate patent CN116710100 when developing similar drugs?
A5: Conduct comprehensive freedom-to-operate (FTO) analyses, evaluate the scope of claims, explore design-around strategies if necessary, and consider patent licensing or collaboration opportunities.
References
[1] CNIPA Patent Database: CN116710100.
[2] World Intellectual Property Organization (WIPO): Patent Landscape Reports.
[3] China Patent Law and Regulations, 2020 Edition.
